BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 8806005)

  • 1. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
    Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
    Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model.
    Ke HZ; Chen HK; Simmons HA; Qi H; Crawford DT; Pirie CM; Chidsey-Frink KL; Ma YF; Jee WS; Thompson DD
    Bone; 1997 Jan; 20(1):31-9. PubMed ID: 8988345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.
    Sato M; Turner CH; Wang T; Adrian MD; Rowley E; Bryant HU
    J Pharmacol Exp Ther; 1998 Oct; 287(1):1-7. PubMed ID: 9765314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LY353381 x HCl: an improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1-34).
    Sato M; Zeng GQ; Rowley E; Turner CH
    Endocrinology; 1998 Nov; 139(11):4642-51. PubMed ID: 9794476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model.
    Lee YS; Gupta R; Kwon JT; Cho DC; Seo YJ; Seu SY; Park EK; Han I; Kim CH; Sung JK; Kim KT
    Spine J; 2018 Oct; 18(10):1877-1887. PubMed ID: 29793000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.
    Ke HZ; Chen HK; Qi H; Pirie CM; Simmons HA; Ma YF; Jee WS; Thompson DD
    Bone; 1995 Nov; 17(5):491-6. PubMed ID: 8579962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats.
    Sato M; Rippy MK; Bryant HU
    FASEB J; 1996 Jun; 10(8):905-12. PubMed ID: 8666168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat.
    Martel C; Picard S; Richard V; Bélanger A; Labrie C; Labrie F
    J Steroid Biochem Mol Biol; 2000 Sep; 74(1-2):45-56. PubMed ID: 11074355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
    Black LJ; Sato M; Rowley ER; Magee DE; Bekele A; Williams DC; Cullinan GJ; Bendele R; Kauffman RF; Bensch WR
    J Clin Invest; 1994 Jan; 93(1):63-9. PubMed ID: 8282823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats.
    Sato M; Bryant HU; Iversen P; Helterbrand J; Smietana F; Bemis K; Higgs R; Turner CH; Owan I; Takano Y; Burr DB
    J Pharmacol Exp Ther; 1996 Oct; 279(1):298-305. PubMed ID: 8859007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women.
    Draper MW; Flowers DE; Huster WJ; Neild JA; Harper KD; Arnaud C
    J Bone Miner Res; 1996 Jun; 11(6):835-42. PubMed ID: 8725181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
    Armamento-Villareal R; Sheikh S; Nawaz A; Napoli N; Mueller C; Halstead LR; Brodt MD; Silva MJ; Galbiati E; Caruso PL; Civelli M; Civitelli R
    J Bone Miner Res; 2005 Dec; 20(12):2178-88. PubMed ID: 16294271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.
    Sutherland MK; Brady H; Gayo-Fung LM; Leisten J; Lipps SG; McKie JA; O'Leary E; Patnaik N; Anderson DW; Bhagwat SS; Stein B
    Calcif Tissue Int; 2003 Jun; 72(6):710-6. PubMed ID: 14563000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of raloxifene on tibia histomorphometry in ovariectomized rats.
    Evans G; Bryant HU; Magee D; Sato M; Turner RT
    Endocrinology; 1994 May; 134(5):2283-8. PubMed ID: 8156931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
    Qu Q; Zheng H; Dahllund J; Laine A; Cockcroft N; Peng Z; Koskinen M; Hemminki K; Kangas L; Väänänen K; Härkönen P
    Endocrinology; 2000 Feb; 141(2):809-20. PubMed ID: 10650964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats.
    Sato M; McClintock C; Kim J; Turner CH; Bryant HU; Magee D; Slemenda CW
    J Bone Miner Res; 1994 May; 9(5):715-24. PubMed ID: 8053401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.
    Nuttall ME; Bradbeer JN; Stroup GB; Nadeau DP; Hoffman SJ; Zhao H; Rehm S; Gowen M
    Endocrinology; 1998 Dec; 139(12):5224-34. PubMed ID: 9832463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression profiling of rat femur revealed suppression of bone formation genes by treatment with alendronate and estrogen but not raloxifene.
    Helvering LM; Liu R; Kulkarni NH; Wei T; Chen P; Huang S; Lawrence F; Halladay DL; Miles RR; Ambrose EM; Sato M; Ma YL; Frolik CA; Dow ER; Bryant HU; Onyia JE
    Mol Pharmacol; 2005 Nov; 68(5):1225-38. PubMed ID: 16079270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective estrogen receptor modulators: an alternative to hormone replacement therapy.
    Bryant HU; Dere WH
    Proc Soc Exp Biol Med; 1998 Jan; 217(1):45-52. PubMed ID: 9421206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats.
    Goss PE; Qi S; Cheung AM; Hu H; Mendes M; Pritzker KP
    J Steroid Biochem Mol Biol; 2004 Sep; 92(1-2):79-87. PubMed ID: 15544933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.